Is Januvia (Sitagliptin) Contraindicated in Heart Failure?
Januvia (sitagliptin) is NOT contraindicated in heart failure, but it should be avoided when possible in favor of superior alternatives, particularly SGLT2 inhibitors. 1
Guideline Recommendations
The 2019 AHA/HFSA scientific statement explicitly addresses DPP-4 inhibitors in heart failure and provides clear guidance 1:
- DPP-4 inhibitors should be avoided in HF because some agents in this class increase the risk of HF hospitalization
- Critical exception: Sitagliptin shows no increased HF signal in clinical trials, distinguishing it from other DPP-4 inhibitors like saxagliptin
- The guidelines recommend avoiding DPP-4 inhibitors as a class in patients with established HF (both HFrEF and HFpEF), with the caveat that sitagliptin specifically did not demonstrate increased HF risk 1
The 2022 ACC/AHA/HFSA Heart Failure Guidelines reinforce prioritizing SGLT2 inhibitors over other glucose-lowering agents in patients with HF and diabetes 2.
FDA Label Information
The Januvia FDA label does not list heart failure as a contraindication 3. The label notes:
- No clinically meaningful changes in vital signs or ECG were observed
- In cardiovascular outcome studies, sitagliptin can be used in patients with established cardiovascular disease
- No specific warnings about heart failure initiation or worsening
Clinical Trial Evidence
The TECOS trial (14,671 patients, median 3-year follow-up) provides the strongest evidence 4, 5:
- Sitagliptin showed no increased risk of HF hospitalization (HR 1.00; 95% CI 0.83-1.19)
- No difference in total HF events including recurrent hospitalizations
- Post-HF hospitalization mortality was similar between groups
- No heterogeneity across 21 patient subgroups, including those with baseline HF
Conflicting observational data exists but is of lower quality:
- Two 2014 retrospective cohort studies suggested increased HF hospitalization risk with sitagliptin 6, 7
- However, these observational studies are superseded by the larger, higher-quality TECOS randomized trial
- A 2014 meta-analysis showed mixed signals across DPP-4 inhibitors, with heterogeneity between agents 8
Clinical Algorithm
For patients with diabetes and heart failure:
First-line: SGLT2 inhibitors (empagliflozin or dapagliflozin) - proven to reduce HF hospitalizations and mortality 1, 2, 9
Second-line: Metformin (if eGFR >30 mL/min) 1
If additional glucose control needed:
Avoid entirely: Thiazolidinediones (pioglitazone, rosiglitazone) - these ARE contraindicated in HF 1
Key Clinical Caveats
- Sitagliptin is not contraindicated but is suboptimal: While safe, it provides no cardiovascular benefit, unlike SGLT2 inhibitors which actively reduce HF events
- Class effect confusion: The DPP-4 inhibitor class shows heterogeneity - saxagliptin increases HF risk, but sitagliptin does not 1, 5
- Recent HF decompensation: Exercise additional caution when initiating any glucose-lowering agent during or immediately after acute decompensation 1
- Renal function matters: Unlike SGLT2 inhibitors which require eGFR >20-30, sitagliptin can be dose-adjusted for severe renal impairment 3
Bottom line: Sitagliptin can be used safely in heart failure patients when SGLT2 inhibitors are contraindicated or not tolerated, but it should not be the first choice given the proven benefits of SGLT2 inhibitors in this population.